Foxo1 links hyperglycemia to LDL oxidation and eNOS dysfunction in vascular endothelial cells
- Jun Tanaka1,
- Qiang Li1,
- Alexander S. Banks1,
- Carrie L. Welch1,
- Michihiro Matsumoto1,
- Tadahiro Kitamura2,
- Yukari Ido-Kitamura2,
- Ronald A. DePinho3 and
- Domenico Accili (da230{at}columbia.edu)1
- 1Department of Medicine, College of Physicians and Surgeons of Columbia University, New York, NY 10032, USA
- 2Metabolic Signal Research Center, Institute for Molecular and Cellular Regulation, Gunma University, Maebashi, Gunma, 371-8512, Japan
- 3Center for Applied Cancer Science, Departments of Medical Oncology, Medicine and Genetics, and Belfer Institute for Innovative Cancer Science, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115
Abstract
Objective– Atherosclerotic cardiovascular disease is the leading cause of death among diabetics. Generation of oxidized low-density lipoproteins (oxLDL) and reduced nitric oxide (NO) availability due to eNOS dysfunction are critical events in atherosclerotic plaque formation. But the biochemical mechanism leading from hyperglycemia to oxLDL formation and eNOS dysfunction is unknown.
Research design and methods– Here we show that glucose, acting through oxidative stress, activates the transcription factor Foxo1 in vascular endothelial cells.
Results– Foxo1 promotes iNOS-dependent NO-peroxynitrite generation, which leads in turn to LDL oxidation and eNOS dysfunction. We demonstrate that Foxo1 gain-of-function mimics the effects of hyperglycemia on this process, while conditional Foxo1 knockout in vascular endothelial cells prevents it.
Conclusions– The findings reveal a hitherto unsuspected role of the endothelial iNOS-NO-peroxynitrite pathway in lipid peroxidation and eNOS dysfunction, and suggest that Foxo1 activation in response to hyperglycemia brings about proatherogenic changes in vascular endothelial cell function.
Footnotes
-
- Received February 10, 2009.
- Accepted June 23, 2009.
- Copyright © American Diabetes Association











